Research Article
Inhibition of the SARS-CoV-2 Main Protease by Isoquercitrin γ-Cyclodextrin Inclusion Complex Formulations: A Biochemical and In Silico Study
Table 1
Inhibition of SARS-CoV-2 main protease (Mpro) by selected compounds.
| | Formulation (active compound) | Control (uninhibited reaction) | Positive control (tannic acid) | SunActive DCD™ (diosmetin-7-O-glucoside) | SunActive HCD™ (hesperetin-7-O-glucoside) | SunActive NCD™ (naringenin-7-O-glucoside) | SunActive QCD™ (quercetin-3-O-glucoside) |
| | V0 | 0.15 | −0.001 | 0.16 | 0.19 | 0.13 | 0.006 | | Inhibition | −/− | Active | Not active | Not active | Not active | Active | | IC50 | −/− | 2.1 μM ± 0.2 μM [3] | −/− | −/− | −/− | 87.9 μM ± 0.9 μM |
|
|
Assays were performed with 10 μM substrate-peptide, 500 μM active compounds, and 1 μM enzyme.
|
